Advanced/Metastatic Solid Tumors
25
10
12
5
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
20.0%
5 terminated out of 25 trials
50.0%
-36.5% vs benchmark
0%
0 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (25)
A Phase I Clinical Study of HLX316 in Participants With Advanced/Metastatic Solid Tumors
A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors
A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (a KAT6A/B Inhibitor) in Patients With Advanced/Metastatic Solid Tumor
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and PK of HLX48 in Advanced/Metastatic Solid Tumors
A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors
Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors
A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients
Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)
Study of MHB088C for Patients With Advanced Solid Malignant Tumors
A Phase I/II of HRS-6719 in Patients With Advanced/Metastatic Solid Tumors
First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)
Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors
ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors
A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors